David H Aggen, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared a post on X:
“Would also highlight an IST run by Tian Zhang at UTSW is evaluating Enfortumab Vedotin + RT for cisplatin-ineligible patients with MIBC. Variant mixed histology tumors are included in this trial.
More about variant histologies here at Uromigos.
Quick review of variant histology UC here.”
More posts featuring Tian Zhang.